Contact
searchSearch
HMP Global
Login

Myelofibrosis

Myelofibrosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Claire Harrison, MD
Videos
Selinexor Plus Ruxolitinib as a Frontline Combination in Patients With Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Claire Harrison, MD
Videos
First-in-Class Mutant CALR Antibody Demonstrates Durable Clinical Activity in Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Prithviraj Bose, MD
Videos
Earlier Momelotinib Treatment May Improve Outcomes in Myelofibrosis
06/23/2026
Prithviraj Bose, MD
Prithviraj Bose, MD, discusses post hoc analyses from the SIMPLIFY-1 and MOMENTUM trials showing that momelotinib provides meaningful spleen, symptom, and anemia benefits across myelofibrosis risk groups, with several outcomes appearing more...
Prithviraj Bose, MD, discusses post hoc analyses from the SIMPLIFY-1 and MOMENTUM trials showing that momelotinib provides meaningful spleen, symptom, and anemia benefits across myelofibrosis risk groups, with several outcomes appearing more...
Prithviraj Bose, MD, discusses...
06/23/2026
Oncology
Andrew Kuykendall, MD
Conference Coverage
Rusfertide Improves Hematocrit Control for Certain Patients With Myeloproliferative Neoplasms
06/03/2025
Andrew Kuykendall
Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses...
06/03/2025
Oncology
Daehyun Lee, MD
Conference Coverage
Pulmonary Hypertension Prevalent Among Patients With Myelofibrosis
06/03/2025
Daehyun Lee,  MD
Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.
Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.
Daehyun Lee, MD, discusses...
06/03/2025
Oncology
Lucía Pérez-Lamas, MD
Videos
Momelotinib Demonstrates Real-World Efficacy, Improved Anemia Symptoms Among Patients With Myelofibrosis
02/07/2025
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of...
02/07/2025
Oncology
John Mascarenhas, MD
Videos
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
01/29/2025
John Mascarenhas, MD
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated...
01/29/2025
Oncology
Prithviraj Bose, MD
Videos
Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis
07/25/2024
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares...
07/25/2024
Oncology
John Mascarenhas, MD
Videos
Examining Real-World Outcomes Among Patients With Myelofibrosis Treated With Pacritinib
07/17/2024
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares...
07/17/2024
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Q&As
Elritercept Well-Tolerated, Demonstrates Potential Efficacy for the Treatment of Patients With Myelofibrosis
07/11/2024
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP,...
07/11/2024
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use